98%
921
2 minutes
20
Key Clinical Message: Administering azathioprine or infliximab for UC and AS treatment carries a significant risk of adverse reactions. Here, we present the case diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months, and subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.
Abstract: Drug-induced myopathy is an uncommon form of muscle injury that can arise in patients without preexisting muscle conditions when exposed to therapeutic doses of certain medications. Administering azathioprine or infliximab for ulcerative colitis (UC) and ankylosing spondylitis (AS) treatment carries a significant risk of adverse reactions, including drug-induced myopathy and increased susceptibility to opportunistic infections. However, occurrences of myopathy induced by the combination of azathioprine and infliximab are rarely reported in clinical practice. Here, we present the case of a 37-year-old male patient diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months. Despite the resolution of symptoms and improvement in intestinal mucosal inflammation observed via endoscopy, the patient subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126648 | PMC |
http://dx.doi.org/10.1002/ccr3.8998 | DOI Listing |
Radiology
August 2025
Department of Radiology, Hospital CUF Tejo, Avenida 24 de Julho 171A, 1350-352 Lisbon, Portugal.
A 36-year-old woman with an otherwise unremarkable medical history was diagnosed with moderate to severe Crohn disease and was started on infliximab. One year later, infliximab was discontinued due to intolerance, and the patient began azathioprine and mesalazine treatment, achieving stable disease. Eight months after discontinuing infliximab, during a Crohn disease flare-up, an urgent abdominal CT examination was performed, partially documenting the lung bases.
View Article and Find Full Text PDFOrphanet J Rare Dis
August 2025
Department of Gastroenterology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, Henan, China.
Objective: To described clinical and genetic characteristics of 4 patients presenting A20 haploinsufficiency (HA20) treated at Children's hospital affiliated to Zhengzhou university from 2015 to 2024.
Methods: A retrospective analysis was conducted on the clinical data, genetic testing results, and treatment outcomes of four children with HA20 treated at the Children's hospital affiliated to Zhengzhou university from 2015 to 2024.
Results: All four patients developed symptoms before the age of 1 year, presenting with recurrent fever and abdominal pain with diarrhea.
Pharmacoeconomics
August 2025
Department of Gastroenterology, Rijnstate Hospital, Arnhem, The Netherlands.
Objectives: The clinical pathway for patients with moderate-to-severe Crohn's disease (CD) typically includes sequential pharmacologic treatment as well as surgery, but positioning of different therapies within these sequences remains challenging. Cost-utility analysis rarely captures these sequences and does not incorporate registry data on long-term effectiveness. In this study, we aim to overcome these limitations.
View Article and Find Full Text PDFJ Gastrointest Surg
August 2025
Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL, United States. Electronic address:
Background: Postoperative recurrence of Crohn's disease is common. Prophylactic medical treatment against recurrence is advocated, but the most effective regimen is still debatable. This network meta-analysis aimed to compare different types of medical treatments for trying to prevent Crohn's disease recurrence.
View Article and Find Full Text PDFPharmacogenomics
August 2025
Centre for Quality Management of Medicines, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Inflammatory bowel disease (IBD) poses a major therapeutic challenge due to its chronic course and variable treatment responses. Genetic polymorphisms significantly influence drug efficacy, prompting this review to analyze their role in treatment non-response. A systematic literature search (PubMed/Scopus) using terms like "genetic polymorphism," "non-response," and "IBD" identified 25 relevant studies.
View Article and Find Full Text PDF